Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Lyon – page 137

2 221 clinical trials in Lyon, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Lyon at a glance
2 221
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

2 221 trials in Lyon

Open in trial search

Neoplasm malignant

Not recruiting

Study on the Safety and Effectiveness of Vidutolimod and Cemiplimab for Adults with Advanced or Metastatic Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Non-small cell lung cancer

Not recruiting

Study on Methotrexate, Dexamethasone, and Montelukast to Prevent Infusion Reactions in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Ceralasertib and Durvalumab with Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Lung neoplasm malignant

Not recruiting

Study on Durvalumab and Domvanalimab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:AstraZeneca AB

Haemophilia B with anti factor IX+1

Not recruiting

Study on How Concizumab Works for Patients with Hemophilia A or B with Inhibitors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Autoimmune demyelinating disease

Not recruiting

Study on the Effects of Satralizumab for Patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Primary progressive multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Crohn's disease

Not recruiting

Study on the Effects of Ozanimod for Children with Moderate to Severe Crohn's Disease Not Responding to Usual Treatments

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Follicular lymphoma

Not recruiting

Study on the Effectiveness and Safety of Tisagenlecleucel for Adults with Hard-to-Treat or Returning Follicular Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tisagenlecleucel
  • Sponsor:Novartis Pharma AG

Non-small cell lung cancer

Not recruiting

Comparison of Sotorasib versus Docetaxel in Previously Treated Non-Small Cell Lung Cancer Patients with KRAS p.

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Amgen Inc.

Diffuse large B-cell lymphoma refractory+1

Not recruiting

Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Lyon

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for endometrial carcinoma, bladder cancer, and various solid tumors. Current research explores combination therapies with novel immunotherapy approaches.

  • Triple-negative breast cancer treatments
  • Gastric and esophageal cancer therapies
  • Advanced pancreatic adenocarcinoma

Multiple studies are evaluating targeted therapies and immunological approaches for various tumor types.

02 Immunology and Infectious Diseases

Groundbreaking research in immune system modulation and infectious disease prevention, including studies on COVID-19 vaccines and immune response in critical conditions.

  • Novel COVID-19 intranasal vaccine development
  • Yellow fever vaccine studies
  • ICU-acquired immunosuppression treatment

Focus on developing innovative vaccination strategies and immune system interventions.

03 Chronic Conditions

Studies addressing long-term health conditions, with particular emphasis on kidney disease, cardiovascular health, and metabolic disorders.

  • Chronic kidney disease management
  • Heart failure prevention
  • Hypertriglyceridemia treatment

Innovative approaches combining established and experimental treatments for improved patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.